Phase 2 Stomach Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- A laboratory test (such as a biopsy or cell sample) has confirmed a cancer diagnosis.
- The person is aged 18 or older and is expected to live for more than 3 months.
- Liver function falls within a specific range, measured by a scoring system called Child-Pugh class A or B (confirm with trial site for exact score requirements).
- Overall physical functioning is relatively good, measured by a scale called ECOG score of less than 2 (meaning the person is able to carry out basic daily activities).
- Blood clotting ability is either normal or can be corrected to a safe level.
- Recent blood test results (taken within 7 days before the procedure) meet specific levels for white blood cells, haemoglobin, platelets, clotting time, kidney function, albumin (a blood protein), and bilirubin (a liver marker) — confirm exact values with the trial site.
- At least one tumour that can be measured using standard imaging guidelines (RECIST v1.1).
- Appropriate birth control measures are in place during treatment.
- The person is willing and able to attend scheduled visits, follow the treatment plan, and complete required tests.
Who may not be able to join:
- People who have taken part in another clinical trial within the past 4 weeks.
- People who have fluid build-up in the abdomen (ascites), a condition where the brain is affected by liver disease (hepatic encephalopathy), or bleeding from swollen veins in the food pipe or stomach.
- People with serious other health conditions — such as heart disease, poorly controlled diabetes, or psychiatric disorders — that may affect outcomes.
- People who currently have, or have a past history of, another type of cancer.
- People who are pregnant or breastfeeding.
- People who are unlikely to follow the trial requirements reliably.
- People for whom the liver artery procedure used in this trial is not safe, including those with: very low platelet counts or poor clotting function; kidney failure requiring dialysis; severe hardening of the arteries; or uncontrolled high blood pressure above 160/100 mmHg.
- People with a known allergy to contrast dye (a substance used during imaging procedures).
- People taking medications that could interfere with how the study drugs are absorbed or processed by the body.
- People whom the trial investigators determine are otherwise not suitable for the trial.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Zhenfeng Zhang, MD, PHD, Second Affiliated Hospital of Guangzhou Medical University
Phone: +862039195966
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Safety of 3 drugs combination treatment; Progression-free survival; Disease control rate; Duration of remission (DOR)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.